Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Terminated · Phase 1 · NCT05737706
Conditions: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 14
- Sites paid
- 12
- Planned or actual enrollment
- 63
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- MRTX1133 (drug)
- Dates
- Started 2023-03-06; completion 2025-03-10
- Results posted
- Not yet
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
From ClinicalTrials.gov, last updated 2025-04-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.2M in research payments for this study in 2025 (15 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tanios S. Bekaii-saab, M.D. Hematology & Oncology · Scottsdale, AZ
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Elena G. Chiorean, M.D. Medical Oncology · Chicago, IL
- Haeseong Park, MD Medical Oncology · Boston, MA
- Colin D. Weekes, MD Medical Oncology · Boston, MA
- Nilofer S. Azad, MD Medical Oncology · Baltimore, MD
- Sreenivasa Chandana, MD Hematology & Oncology · Grand Rapids, MI
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- Yonina R. Murciano-goroff, MD, DPHIL Internal Medicine · New York, NY
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute, Llc $318,008
- Lee Daeyeol Mms $154,334
- Ut MD Anderson Cancer Center $152,125
- Next Oncology $109,793
- University of Washington Medical Ctr, WA $98,498
- South Texas Accelerated Research Therapeutics, Llc $76,833
- Mayo Clinic Hospital, AZ $71,261
- Dana-Farber Cancer Institute $68,330
- The Start Center for Cancer Care $59,631
- Memorial Sloan-Kettering Cancer Center - Cancer $57,101
- Johns Hopkins University $54,822
- Start Midwest $5,344
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.